Member Info for Fredd1eboy

Well done. Normality resumed. Best wishes. Freddie

Cannot stand it. I'm out until it stops

if I wanted to sell 1m shares online in one hit, I can get 2.9861p. Hoping for a move back up to 3p soon. Still wont sell, of course. Freddie

to sell 1m shares online in one hit, I can get 2.97p. Hoping for a move back up to 3p soon. Still wont sell, of course. Freddie

now even tighter

Hi All. I'm hoping Olav and Micheal kept off the subject in order to maximise impact of results when issued. Well thats straight from my rose coloured tints, but would be great if I am correct and results good. Best wishes. Freddie

Now increased to 2.9577p for 1m

Currently being offered 2.955p for 1m shares and 3.145 to buy. Someones still after our shares minded they are prepared to purchase 1m in one hit online trading. Up the anti by 100% and I might, only might, be prepared to part with a few!

https://clinicaltrials.gov/ct2/show/NCT01916369?term=Reneuron&rank=3 Shouldnt think we have too long to wait now!

Couldnt agree more Sisyphus. Time will tell. Just hope that safe drugs with real promise are fast tracked as our pressurised health service needs all the help it can get. Have a good day. Freddie

Irrespective of our opinions, there are many out there that know far more than you and I. Some will be advising on whether or not approval for progressing to Pisces 3 will be given. Others will and probably are currently advising cautious institutional investors. Others will be trying the manipulate the M. market for self gain... They are the ones we have to Be cautious of...derampers and rampers....who I suspect are currently very active. Personally I am positive for the future, but do wear rose coloured tints. Have a good day. Freddie

Extract 2017 – a year of progress While primary investor focus has been on the read-out of the stroke study, there are a number of other programmes with potential upcoming newsflow. This includes CLI study (Phase I data read-out and Phase II start in H117), RP study (Phase I/II safety and efficacy data read-out 2017) and further preclinical data from the exosome nanomedicine programme and potential move into the clinic in H118. Valuation: Increased to £278m Our rNPV-based valuation has increased to £278m (vs £249m) or 9p/share (vs 7.9p), after increasing the probability of success in the CTX stroke programme to 25% (vs 20%) and using H117 reported cash. Our CLI and RP study assumptions remain the same. We have reduced R&D spend in 2017 and 2018 slightly to reflect a lower than expected cash burn in H117. ReNeuron is well funded to execute on its expanding clinical trial programme, including the pivotal controlled clinical stroke study due to start 2017.

http://www.proactiveinvestors.co.uk/companies/stocktube/6569/reneuron-cfo-very-encouraged-with-stroke-study-results-6569.html

Taken us back 4% I can almost predict it these days. After all I've had a lot of practice over the years!

.....with so many late sells will we or will we not drop back. Will soon know? Best of luck all. Freddie

Are they just teasing or is it a recovery shoot sprouting from the ashes! Time will tell

Fair doos. But I enjoy a tease. Honestly. Best wishes. Fred

They are teasing us now!

......2.9001p on a sale trade of 1m stock. 3p just around the the corner

confirmed 10:46:30 2.9375 25,000 734.37